宜宾隆鼻玻尿酸能管几年(宜宾激光美白祛斑哪家好) (今日更新中)

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

KATHMANDU, Aug. 3 (Xinhua) -- Two glaciers in Nepal that shrank at an accelerated rate in the past 10 years compared to preceding decades will inevitably disappear from rising temperatures as no fresh snow supply is expected for them, a new research by Japan's Nagoya University says.According to Wednesday's Republica daily, the masses of the Yala glacier of Langtang Himal in central Nepal and the AX010 glacier of Shorong Himal in the Khumbu region shrank annually by 0. 8 meters and 0.81 meters respectively in the 2000s, which was a significant acceleration from the 0.68 and 0.72 meters of shrinkage per year between 1970 and 1990, said findings of the research published in a journal of the National Academy of Sciences of the United States on Tuesday."If the trend since the 1990s continues for the Yala and AX010 glaciers, the disappearance of these glaciers is inevitable because they are about to lose their accumulation areas, thus, no snow supply is expected for these glaciers," says the research conducted by Koji Fujita and Takayuki Nuimura.The researchers also found that while the shrinking of glaciers has accelerated in humid environments, the opposite is true for those in arid environments. The shrinking of Rikha Samba glacier located in the Kaligandaki Hidden Valley slowed from 0.57 meters per year between 1970 and 1990 to 0.48 meters per year in the 2000s."A comparison of the mass balance results and annual precipitation reveals that glacier wastage has been accelerated in humid environments but suppressed in an arid environment," the research says.Apart from environment, altitude also appears to play a role in the lifespan of glaciers, the researchers say. Rikha Samba is located at an altitude of 5,700 meters where loss of mass from melting could be compensated to some extent by collection of snowfall.The Yala glacier and AX010, on the other hand, are located at lower altitudes of 5,400 meters and 5,200 meters respectively.

MOSCOW, Aug. 26 (Xinhua) -- Russia will carry out two unmanned test launches of Soyuz carrier rockets in the coming fall before delivering crews to the International Space Station (ISS), local media reported on Friday.Citing a source, RIA Novosti news agency said that one of the Soyuz rockets was scheduled to send a new Progress M-13M space freighter to the ISS.On Wednesday, a Progress M-12M cargo ship failed to reach the orbit after the engine of a Soyuz-U carrier rocket turned off during the ascend. Soon after the accident, Russia announced it will temporarily ground all Soyuz rockets.Due to the accident, Russian space authorities have put off Thursday's launch of a Soyuz-2 carrier rocket from the Plesetsk Space Center in northern Russia and a launch of a manned space ship from Baikonur space center in Kazakhstan.After the retirement of the U.S. shuttle fleet, Russia's Soyuz spacecrafts have become the only way for astronauts to reach the ISS until at least the middle of the decade.

KATHMANDU, Aug. 7 (Xinhua) -- Ban on smoking in public places will be enforced from Sunday with the Tobacco Control and Regulatory Act-2010 coming into effect.Those smoking in public places will be fined and civil servants will be liable to departmental action.Government offices, corporations, educational institutions, libraries, airports, public vehicles, orphanages, childcare centres, cinema halls, homes for the elderly, cultural centres, children's gardens, hotels, restaurants, resorts, girls' and boys' hostels, department stores, religious sites and industries have been designated no-smoking zones.Health Secretary Sudha Sharma said mass awareness campaign highlighting punishment will be carried out. She also said an inter-ministerial coordinating committee has been formed to enforce the law to ensure people's right to health. Pasting no- smoking notices at every public place will be mandatory.According to The Himalayan Times daily, the ban covers sale of tobacco products and single sticks within a 100-meter radius of educational and health institutions, children's homes, child care centers and home for elders.Anyone selling tobacco products to persons under the age of 18 years and pregnant women will be fined.The Act also prohibits advertising and sponsoring programs in the name of tobacco-related products through media. Offenders will be fined.The government's mass awareness campaign will cover the entire country to ensure effective implementation of the Act.

WASHINGTON, July 27 (Xinhua) -- Astronomers studying observations taken by NASA's Wide-field Infrared Survey Explorer (WISE) mission have discovered the first known "Trojan" asteroid orbiting the sun along with Earth, the U.S. National Aeronautics and Space Administration (NASA) announced Wednesday in a statement.Trojans are asteroids that share an orbit with a planet near stable points in front of or behind the planet. Because they constantly lead or follow in the same orbit as the planet, they never can collide with it. In our solar system, Trojans also share orbits with Neptune, Mars and Jupiter. Two of Saturn's moons share orbits with Trojans.Scientists had predicted Earth should have Trojans, but they have been difficult to find because they are relatively small and appear near the sun from Earth's point of view."These asteroids dwell mostly in the daylight, making them very hard to see," said Martin Connors of Athabasca University in Canada, lead author of a new paper on the discovery to be published Thursday in the journal Nature. "But we finally found one, because the object has an unusual orbit that takes it farther away from the sun than what is typical for Trojans. WISE was a game-changer, giving us a point of view difficult to have at Earth 's surface."The WISE telescope scanned the entire sky in infrared light from January 2010 to February 2011. Connors and his team began their search for an Earth Trojan using data from NEOWISE, an addition to the WISE mission that focused in part on near-Earth objects, or NEOs, such as asteroids and comets. NEOs are bodies that pass within 28 million miles (45 million kilometers) of Earth 's path around the sun. The NEOWISE project observed more than 155, 000 asteroids in the main belt between Mars and Jupiter, and more than 500 NEOs, discovering 132 that were previously unknown.The team's hunt resulted in two Trojan candidates. One called 2010 TK7 was confirmed as an Earth Trojan after follow-up observations with the Canada-France-Hawaii Telescope on Mauna Kea in Hawaii.The asteroid is roughly 1,000 feet (300 meters) in diameter. It has an unusual orbit that traces a complex motion near a stable point in the plane of Earth's orbit, although the asteroid also moves above and below the plane. The object is about 50 million miles (80 million kilometers) from Earth. The asteroid's orbit is well-defined and for at least the next 100 years, it will not come closer to Earth than 15 million miles (24 million kilometers).

来源：资阳报